Seasonal influenza virus vaccine high-dose - Sanofi Pasteur

Drug Profile

Seasonal influenza virus vaccine high-dose - Sanofi Pasteur

Alternative Names: Fluzone HD; Fluzone® High Dose IM; Fluzone® High-Dose influenza vaccine; High-Dose Influenza Vaccine Quadrivalent; Seasonal influenza virus vaccine - sanofi pasteur

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi K.K.; Sanofi Pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 18 Sep 2017 Sanofi Pasteur completes enrolment in a phase III trial for Influenza virus infections (In the elderly, Prevention) in USA (NCT03282240)
  • 15 Sep 2017 Phase-I/II clinical trials in Influenza virus infections (In the elderly, Prevention, In volunteers) in Japan (IM) (NCT03233217)
  • 15 Sep 2017 Phase-I/II clinical trials in Influenza virus infections (In the elderly, Prevention, In volunteers) in Japan (SC) (NCT03233217)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top